Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ.

Neuro Oncol. 2009 Dec;11(6):842-52. doi: 10.1215/15228517-2009-005.

2.

Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.

Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, Nelson SJ, Pirzkall A.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):381-9. Epub 2007 May 21.

3.

Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy.

Farace P, Amelio D, Ricciardi GK, Zoccatelli G, Magon S, Pizzini F, Alessandrini F, Sbarbati A, Amichetti M, Beltramello A.

J Neurooncol. 2013 Jan;111(2):177-85. doi: 10.1007/s11060-012-0997-y. Epub 2012 Dec 22.

PMID:
23264191
4.

Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.

Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ.

Neuro Oncol. 2012 Jul;14(7):942-54. doi: 10.1093/neuonc/nos128. Epub 2012 Jun 18.

5.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.

J Neurooncol. 2009 Jan;91(1):69-81. doi: 10.1007/s11060-008-9685-3. Epub 2008 Sep 23.

6.

CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.

Matheus MG, Castillo M, Ewend M, Smith JK, Knock L, Cush S, Morris DE.

AJNR Am J Neuroradiol. 2004 Aug;25(7):1211-7.

7.

3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.

Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):126-37.

PMID:
15093908
8.

Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.

Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH.

Radiology. 2014 Dec;273(3):831-43. doi: 10.1148/radiol.14132868. Epub 2014 May 30.

PMID:
24885857
9.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.

J Neurooncol. 2009 Feb;91(3):337-51. doi: 10.1007/s11060-008-9719-x. Epub 2008 Nov 15.

10.

Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.

Heo YJ, Kim HS, Park JE, Choi CG, Kim SJ.

PLoS One. 2015 Aug 21;10(8):e0136380. doi: 10.1371/journal.pone.0136380. eCollection 2015.

11.

Differentiation between brain tumor recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy.

Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, Zarudzki L.

Folia Neuropathol. 2010;48(2):81-92.

12.

Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA.

J Neurosurg. 2014 Nov;121(5):1115-23. doi: 10.3171/2014.7.JNS132449. Epub 2014 Sep 5.

PMID:
25192475
13.

[Prediction of clinical course of glioblastomas by MRI during radiotherapy].

Leitzen C, Schild HH, Bungart B, Herrlinger U, Lütter C, Müdder T, Wilhelm-Buchstab T, Schüller H.

Strahlenther Onkol. 2010 Dec;186(12):681-6. doi: 10.1007/s00066-010-2156-8. Epub 2010 Nov 29. German.

PMID:
21221885
14.

Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.

Paik W, Kim HS, Choi CG, Kim SJ.

Korean J Radiol. 2016 Jan-Feb;17(1):117-26. doi: 10.3348/kjr.2016.17.1.117. Epub 2016 Jan 6.

15.

[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].

Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.

Rofo. 2006 Jun;178(6):627-33. Epub 2006 May 15. German.

PMID:
16703499
16.

Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas.

Chuang CF, Chan AA, Larson D, Verhey LJ, McDermott M, Nelson SJ, Pirzkall A.

Technol Cancer Res Treat. 2007 Oct;6(5):375-82.

PMID:
17877425
17.

Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.

Li Y, Lupo JM, Polley MY, Crane JC, Bian W, Cha S, Chang S, Nelson SJ.

Neuro Oncol. 2011 May;13(5):546-57. doi: 10.1093/neuonc/noq194. Epub 2011 Feb 4.

18.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
19.

Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.

Parra NA, Maudsley AA, Gupta RK, Ishkanian F, Huang K, Walker GR, Padgett K, Roy B, Panoff J, Markoe A, Stoyanova R.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):376-84. doi: 10.1016/j.ijrobp.2014.03.049. Epub 2014 Jul 24.

20.

Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.

Di Costanzo A, Trojsi F, Giannatempo GM, Vuolo L, Popolizio T, Catapano D, Bonavita S, d'Angelo VA, Tedeschi G, Scarabino T.

J Exp Clin Cancer Res. 2006 Sep;25(3):383-90.

PMID:
17167979

Supplemental Content

Support Center